QUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Abstract: in which R¹ to R⁴ are the same or different and are inter alia, each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₄alkanoyl, amino, R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, R¹⁰ is inter alia hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or amino; and A is -(CH₂)₂-, (CH₂)₃- ­ or -CH=CH-; processes for their preparation, pharmaceutical compositions containing them and their use in therapy as inhibitors of gastric acid secretion.

Description: The present invention relates to substituted quinoline derivatives, processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy. Substituted quinoline derivatives are known in the art. For example, in J.Chem.Soc. 1957, 3448, J.Pharm. Soc.Japan 1961, 81 , 363, 1961 and 479, certain 1-(substituted phenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinolines 1-phenyl-4-halo-2,3-dihydropyrrolo[3,2-c]quinolines and 1-phenyl-2,3-dihydropyrrolo[3,2-c]quinolines are disclosed as synthetic intermediates but no therapeutic activity is disclosed for such compounds. In addition, J.Pharm.Soc.Japan 1957, 77 , 85, and ibid. 1961, 90, disclose certain 1-(substituted phenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinolines and report anti-bacterial activity for the compounds but do not disclose formulations containing said compounds or information concerning a specific therapeutic utility for the compounds. It has now been found that certain substituted 2,3-dihydropyrrolo[3,2-c]quinolines are potent inhibitors of the H⁺K⁺ATPase enzyme and as such are useful as antiulcer agents. Accordingly the present invention provides, in a first aspect compounds of structure (I) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₄alkanoyl, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹ are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; provided that (i) when R¹ to R⁷ are each hydrogen, one of R⁸ and R⁹ is hydrogen and the other is hydrogen or methoxy and R¹⁰ is methyl, A is -(CH₂)₃- or -CH=CH-; (ii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R⁷ is hydroxy and R¹⁰ is methyl, A is -(CH₂)₃- or -CH=CH-; (iii) when R¹ to R⁹ are each hydrogen and R¹⁰ is chlorine, A is -(CH₂)₃-; (iv) when R¹ to R¹⁰ are each hydrogen, A is -(CH₂)₃-; (v) when R¹ and R² and R⁴ to R¹⁰ are each hydrogen and R³ is methoxy, A is -(CH₂)₂- or -(CH₂)₃-; (vi) when R² to R⁹ are each hydrogen, R¹⁰ is methyl and R¹ is hydrogen, hydroxy or methoxy, A is -(CH₂)₃- or -CH=CH-; (vii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R¹⁰ is methyl and R⁷ is methyl or methoxy, A is -(CH₂)₃-or -CH=CH-; (viii) when R¹ to R⁸ are each hydrogen, R⁹ is chlorine and R¹⁰ is methyl, A is -(CH₂)₃ or -CH=CH-, (ix) when R¹ and R² and R⁴ to R⁹ are each hydrogen, R¹⁰ is methyl and R³ is hydrogen or methoxy, A is -(CH₂)₂-or -(CH₂)₃-, and pharmaceutically acceptable salts thereof. Suitably A is -(CH₂)₃-, preferably A is -(CH₂)₂- or -CH=CH-. Suitably, R¹ to R⁴ are all hydrogen; more suitably only two of R¹ to R⁴ are hydrogen. Preferably three of R¹ to R⁴ are hydrogen. More preferably R² to R⁴ are hydrogen and R¹ is other than hydrogen. Most preferably R² to R⁴ are hydrogen and R¹ is C₁₋₆alkyl or C₁₋₆alkoxy. Suitably R⁵ to R⁹ are all hydrogen. Preferably three of R⁵ to R⁹ are hydrogen. More preferably R⁵ to R⁸ are all hydrogen and R⁹ is other than hydrogen. Most preferably R⁵ to R⁸ are all hydrogen and R⁹ is C₁₋₆alkyl, in particular, methyl. Suitably R¹⁰ is halogen or C₁₋₆alkylthio. Preferably R¹⁰ is hydrogen, or a group NR¹¹R¹². Suitably R¹¹ and R¹² together with the nitrogen atom to which they are attached form a saturated or unsaturated ring. Preferably R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl. C₁₋₆alkyl groups (either alone or as part of another group) can be straight or branched. It will be appreciated that compounds of structure (I) in which one or more of R¹ to R¹⁰ is a C₃₋₆alkyl group (either alone or as part of another group) may contain an asymmetric centre due to the presence of the C₃₋₆alkyl group. Such compounds will exist as two (or more) optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of the two are included within the scope of the present invention. Further, all diastereomeric forms possible (pure enantiomers and mixtures thereof) are within the scope of the invention. The compounds of the present invention can be prepared by processes analogous to those known in the art. The present invention therefore provides in a further aspect a process for the preparation of a compound of structure (I) or a pharmaceutically acceptable salt thereof which comprises (a) for compounds in which R¹⁰ is hydrogen or C₁₋₆alkyl, cyclisation of a compound of structure in which R¹ to R⁴ are as described for structure (I), and R¹⁰ is as described for structure (I) or a leaving group, n is 2 or 3 and X¹ and X² are leaving groups, in the presence of a compound of structure (III) in which R⁵ to R⁹ are as described for structure (I); or (b) for compounds in which R¹⁰ is other than C₁₋₆alkyl reaction of a compound of structure (IV) in which R¹ to R⁹ and A are as described for structure (I) with a reagent providing the group R¹⁰, and optionally thereafter converting one group R¹⁰ into another group R¹⁰; oxidising a compound in which A is (CH₂)₂ to a compound in which A is -CH=CH-; removing any protecting groups; forming a pharmaceutically acceptable salt. Suitable leaving groups X¹ and X² will be apparent to those skilled in the art and include for example halogen, in particular chlorine. Suitable leaving groups for R¹⁰ will also be apparent to those skilled in the art and include for example C₁₋₄alkylsulphinyl, particularly methylsulphinyl. Suitably the cyclisation of a compound of structure (II) in the presence of a compound of structure (III) is carried out in a solvent and at a temperature of between ambient and the reflux temperature of the solvent used. Preferably the reaction is carried out at elevated temperature under pressure in a suitable solvent. For example, in a solvent such as 2-propanol at a temperature of 160-180° at a pressure of between 300-1000 KPa, (50-150 p.s.i.). Suitable reagents providing the group R¹⁰ will be apparent to those skilled in the art and will of course depend on the nature of the group R¹⁰ sought. For example in the preparation of compounds of structure (I) in which R¹⁰ is halogen, for example chlorine, a suitable compound of structure (IV) can be reacted with phosphorous oxychloride, optionally in the presence of a suitable solvent and at an appropriate temperature; for compounds of structure (I) in which R¹⁰ is NH₂, a suitable compound of structure (IV) can be reacted with phenyl phosphorodiamidate, again optionally in the presence of a suitable solvent at an appropriate temperature. Alternatively, compounds of structure (I) can be prepared from other compounds of structure (I), for example, compounds of structure (I) in which R¹⁰ is halogen can be converted into compounds of structure (I) in which R¹⁰ is other than halogen by reaction with an appropriate nucleophilic reagent capable of displacing the chlorine atom. Suitable nucleophilic reagents include for example an amine such as a C₁₋₄ alkylamine. for example methylamine in a suitable solvent such as methanol; such reagents can be used to form compounds of structure (I) in which R¹⁰ is C₁₋₄alkylamino, particularly, methylamino. In addition compounds of structure (I) in which R¹⁰ is methyl can be converted into compounds of structure (I) in which R¹⁰ is CH₂OH, in two steps, firstly by oxidation of the adjacent ring nitrogen atom with, for example, m-chloroperbenzoic acid followed by rearrangement in the presence of, for example, trifluoroacetic anhydride Further interconversions will be apparent to those skilled in the art, for example, compounds of structure (I) in which A is -(CH₂)₃- and R¹⁰ is hydrogen, can be converted to compounds of structure (IV) in which A is -(CH₂)₃-, in two steps, firstly by oxidation of the quinoline nitrogen atom, with for example, m-chloroperbenzoic acid followed by rearrangement in the presence of, for example, trifluoroacetic anhydride. Suitable reagents for carrying out the oxidation of compounds of structure (I) in which A is (CH₂)₂ to compounds of structure (I) in which A is CH=CH will be apparent to those skilled in the art and include, for example, dehydrogenation in the presence of a noble metal catalyst, in particular palladium-on-carbon. Pharmaceutically acceptable acid addition salts of the compounds of structure (I) can be prepared by standard procedures by, for example, reaction with suitable organic and inorganic acids the nature of which will be apparent to persons skilled in the art. For example, pharmaceutically acceptable salts can be formed by reaction with hydrochloric, sulphuric, or phosphoric acids; aliphatic, aromatic or heterocyclic sulphonic acids or carboxylic acids such as, for example, citric, maleic or fumaric acids. Certain intermediate compounds of structure (II) and (IV) are new. They can be prepared by procedures analogous to those known in the art. For example, compounds of structure (II) can be prepared by heating a compound of structure (V) and a compound of structure (VI) in which, R¹ to R⁴ are as described for structure (I), R¹¹ is hydrogen or C₁₋₄alkyl and A¹ is (CH₂)₂- or -(CH₂)₃- optionally in the presence of a suitable solvent, followed by treatment with, for example, phosphorous oxychloride. Compounds of structure (IV) in which R¹ to R⁴ are the same as R⁶ to R⁹ and R⁵ is hydrogen can be prepared by the reactions outlined in Scheme (I) below. The compounds of structure (IV) so formed can be converted into the corresponding compounds of structure (IV) in which A is CH=CH by oxidation in the presence of a palladium/carbon catalyst. It is to be noted, and apparent to those skilled in the art that in the foregoing reactions, where necessary, groups R¹ to R⁹ will be in protected form when undergoing the procedures described. For example, in carrying out the reaction step (iv) of Scheme 1 any hydroxy or amino groups present in said substituents should be protected. Suitable protecting groups are as described in "Greene, T.W., Protective Groups in Organic Chemistry". The compounds of structure (I) and their pharmaceutically acceptable salts and related compounds for which no pharmaceutical utility has been previously disclosed exert an anti-secretory effect by inhibition of the gastrointestinal H⁺K⁺ATPase enzyme (Fellenius E., Berglindh T., Sachs G., Olke L., Elander B., Sjostrand S.E., and Wahlmark B., 1981, Nature, 290 , 159-61). In a further aspect therefore the present invention provides the compounds of structure (IA) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹ are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; provided that ( i) when R² to R⁹ are each hydrogen, R¹⁰ is methyl and R¹ is hydrogen, hydroxy or methoxy, A is -(CH₂)₃- or -CH=CH-; ( ii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R¹⁰ is methyl and R⁷ is methyl or methoxy, A is -(CH₂)₃- or -CH=CH-; (iii) when R¹ to R⁸ are each hydrogen, R⁹ is chlorine and R¹⁰ is methyl, A is -(CH₂)₃ or -CH=CH-, and pharmaceutically acceptable salts thereof for use in therapy. The compounds of structure (IA) and their pharmaceutically acceptable salts inhibit exogenously and endogenously stimulated gastric acid secretion and are useful in the treatment of gastrointestinal diseases in mammals, in particular humans. Such diseases include, for example, gastric and duodenal ulcers, and Zollinger-Ellison Syndrome. In a still further aspect there is therefore provided the use of compounds of structure (IB) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₆alkanoyl amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹ are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; or a pharmaceutically acceptable salt thereof in the preparation of a medicament for use in the treatment of ulcer disease. Further, the compounds of structure (IB) can be used in the treatment of other disorders where an anti-secretory effect is desirable for example in patients with gastritis, NSAID induced gastritis, gastric ulcers, acute upper intestinal bleeding, in patients with a history of chronic and excessive alcohol consumption, and in patients with gastro oesophageal reflux disease (GERD). In therapeutic use, the compounds of the present invention are usually administered in a standard pharmaceutical composition. The present invention therefore provides in a further aspect pharmaceutical compositions comprising a compound of structure (IB) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The compounds of structure (IB) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges. A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent. A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose. A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule. Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration. A typical suppository formulation comprises a compound of structure (IB) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats. Preferably the composition is in unit dose form such as a tablet or capsule. Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of structure (IB) or a pharmaceutically acceptable salt thereof calculated as the free base. The present invention also provides a method of inhibiting gastric acid secretion which comprises administering to a mammal in need thereof an effective amount of a compound of structure (IB) or a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable compounds of the invention will normally be administered to a subject for the treatment of gastro-intestinal diseases and other conditions caused or exacerbated by gastric acidity. The daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound of structure (IB) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more. In addition, the compounds of the present invention can be co-administered with further active ingredients, such as antacids (for example magnesium carbonate or hydroxide and aluminium hydroxide), non-steroidal anti-flammatory drugs (for example indomethacin, aspirin or naproxen), steroids, or nitrite scavengers (for example ascorbic acid or aminosulphonic acid), or other drugs used for treating gastric ulcers (for example pirenzipine, prostanoids for example 16,16 dimethyl PGE₂, or histamine H₂-antagonists (for example, cimetidine). The following examples illustrate the invention. Temperatures are recorded in degrees centigrade. Example 1 Preparation of 1-(2-methoxyphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 2-Methyl-3-(2-chloroethyl)-4-chloro-8-methoxyquinoline (2.70 g, 10 mmol) and 2-methoxyaniline hydrochloride (1.60 g, 10 mmol) in 1-butanol (40 ml) were heated at reflux for 6 hours then the solvent evaporated, the crude product taken up in dichloromethane, washed with aqueous sodium bicarbonate, dried and evaporated. Trituration with ether and recrystallisation from aqueous methanol gave 1-(2-methoxyphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline (0.62 g, 19%), m.p. 168-169°. C₂₀H₂₀N₂O₂ Found C 74.84, H 6.33, N 8.53 Requires C 74.98, H 6.29, N 8.74 Example 2 Preparation of 1-(2-methylphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 2-Methyl-3-(2-chloroethyl)-4-chloro-8-methoxyquinoline (8.37 g, 31 mmol) and 2-methylaniline hydrochloride (4.45 g, 31 mmol) in 1-butanol (100 ml) were heated at reflux for 5 days, then the solvent evaporated, the crude product taken up in dichloromethane, washed with aqueous sodium bicarbonate, dried and evaporated. Chromatography (silica gel, 2% methanolic ammonia in dichloromethane) and recrystallisation from aqueous ethanol gave 1-(2-methylphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline (2.04 g, 22 %), m.p. 182-183°. C₂₀H₂₀N₂O Found C 79.04, H 6.50, N 9.21 Requires C 78.92, H 6.62, N 9.20 Example 3 Preparation of 1-(2-methylphenyl)-4-methyl-6-hydroxy-2,3-dihydropyrrolo[3,2-c]quinoline 2-Methyl-3-(2-chloroethyl)-4-chloro-8-methoxyquinoline (54 g, 0.2 mol), o-methylaniline hydrochloride (28.7 g, 0.2 mol) and 1-butanol (500 ml) were heated to 170°C in a pressure vessel for 10 hours, then the solvent evaporated. Conversion to free base and chromatography (silica gel, 2% methanolic ammonia in dichloromethane) gave 1-(2-methylphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline in the early fractions. Later fractions were recrystallised from ethyl acetate to yield 1-(2-methylphenyl)-4-methyl-6-hydroxy-2,3-dihydropyrrolo[3,2-c]quinoline, m.p. 144-146°. C₁₉H₁₈N₂O Found C 78.49, H 6.39, N 9.70 Requires C 78.59, H 6.25, N 9.65 Example 4 Preparation of 1-(2-methylphenyl)-4-methyl-6-methoxypyrrolo[3,2-c]quinoline 1-(2-Methylphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline (4.57 g, 15 mmol) in diphenyl ether (50 ml) was heated at reflux with 10% palladium-on-charcoal (1.0 g) for 1 hour then the catalyst removed on celite. Chromatography (silica gel, 1% methanolic ammonia in dichloromethane) and recrystallisation from ethyl acetate/petroleum ether gave 1-(2-methylphenyl)-4-methyl-6-methoxypyrrolo[3,2-c]quinoline(2.2 g, 48%), m.p. 143-145°. C₂₀H₁₈N₂O Found C 79.22, H 6.05, N 9.23 Requires C 79.44, H 6.00, N 9.26 Example 5 Preparation of 1-(2-methylphenyl)-4,6-dimethyl-2,3-dihydropyrrolo[3,2-c]quinoline 2,8-Dimethyl-3-(2-chloroethyl)-4-chloroquinoline (7.63 g, 30 mmol) and 2-methylaniline hydrochloride (4.31 g, 30 mmol) in 1-butanol (100 ml) were heated at reflux for 4 days, then the solvent evaporated, the crude product taken up in dichloromethane, washed with aqueous sodium bicarbonate, dried and evaporated. Chromatography (silica gel, 2% methanolic ammonia in dichloromethane) and recrystallisation from aqueous ethanol gave 1-(2-methylphenyl)-4,6-dimethyl-2,3-dihydropyrrolo-[3,2-c]quinoline (1.95 g, 23%), m.p. 126-128°. C₂₀H₂₀N₂ Found C 83.11, H 7.06, N 9.65 Requires C 83.30, H 6.99, N 9.71 Example 6 Preparation of 1-(2-methylphenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 2-Methyl-3-(2-chloroethyl)-4-chloroquinoline (45 g, 0.16 mol), 2-methylaniline (35 ml, 0.32 mol) and ethanol (300 ml) were heated to 150°C in a pressure vessel for 17 hours, then concentrated in vacuo . The product crystallised as the hydrochloride salt. Conversion to free base and recrystallisation from ethyl acetate yielded 1-(2-methylphenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinoline (19.1 g, 43%), m.p. 148-150°. C₁₉H₁₈N₂ Found C 83.25, H 6.66, N 10.20 Requires C 83.18, H 6.61, N 10.21 Example 7 Preparation of 1-(4-methoxy-2-methylphenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 2-Methyl-3-(2-chloroethyl)-4-chloroquinoline hydrochloride (5.53 g, 20 mmol) and 4-methoxy-2-methylaniline (5.15 ml, 40 mmol) in ethanol (100 ml) were heated at 170°C in a pressure vessel for 24 hours, then the solvent evaporated, the crude product taken up in dichloromethane, washed with aqueous sodium bicarbonate, dried and evaporated. Chromatography (silica gel, 2% methanolic ammonia in dichloromethane) and recrystallisation from aqueous methanol gave 1-(4-methoxy-2-methylphenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinoline (2.04 g, 22 %), m.p. 115-117°. C₂₀H₂₀N₂O. 0.4H₂O Found C 77.07, H 6.70, N 8.85 Requires C 77.09, H 6.73, N 8.99 Example 8 Preparation of 1-(2-methylphenyl)-7-methoxy-1,2,3,4-tetrahydropyridino[3,2-c]quinoline A. Preparation of 3-(2-methoxyphenylaminomethylene)tetrahydropyran-2-one. The sodium salt of 3-(hydroxymethylene)-tetrahydropyran-2-one (25 g, 0.17 mol) and 2-methoxyaniline hydrochloride (32 g, 0.2 mol) in ethanol (750 ml) were warmed to 70°C with stirring for 2 hours, then filtered hot. After evaporation of the ethanol, the crude product was taken up in dichloromethane, washed with dilute hydrochloric acid, dried and evaporated. Trituration with ether gave 3-(2-methoxyphenylaminomethylene)tetrahydropyran-2-one (21.5 g, 55%) as a mixture of E and Z isomers, m.p. 85-100°. B. Preparation of 3-(3-chloropropyl)-4-chloro-8-methoxyquinoline. 3-(2-Methoxyphenylaminomethylene)-tetrahydropyran-2-one (11.67 g, 50 mmol) in phosphoryl chloride (50 ml) was heated at reflux for 1 hour. After cooling, the solution was poured onto ice, the mixture heated to boiling, charcoal added., and the hot solution filtered through celite. Subsequent cooling and addition of sodium hydroxide solution gave a solid which was filtered off and recrystallised from aqueous ethanol to yield 3-(3-chloropropyl)-4-chloro-8-methoxyquinoline (5.6 g, 41%), m.p. 86-89°. C. Preparation of 1-(2-methylphenyl)-7-methoxy-1,2,3,4-tetrahydropyridino[3,2-c]quinoline A solution of 3-(3-chloropropyl)-4-chloro-8-methoxyquinoline (6.4 g, 23.6 mmol) and 2-methylaniline (5.0 ml, 47.2 mmol) in ethanol (250 ml) was heated at reflux for 4 days, then cooled and evaporated. Dichloromethane and aqueous sodium bicarbonate solution were added, and the organic layer washed with water, dried and evaporated. Chromatography (silica gel, 1% methanolic ammonia in dichloromethane) followed by crystallisation from ethyl acetate gave 1-(2-methylphenyl)-7-methoxy-1,2,3,4-tetrahydropyridino-[3,2-c]quinoline (1.92 g, 27%), m.p. 160-161°. C₂₀H₂₀N₂O Found C 78.80, H 6.57, N 9.23 Required C 78.92, H 6.62, N 9.20 Example 9 Preparation of 1-(2-methoxyphenyl)-4-oxo-6-methoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline A. preparation of 2-(2-ethoxyethyl)-N,N′-di(2-methoxyphenyl)malonodiamide A mixture of o-anisidine (45.1 ml, 0.4 mol) and diethyl 2-ethoxyethylmalonate (46.5 g, 0.2 mol) was heated to 200°C as nitrogen was bubbled slowly through the mixture, and ethanol allowed to distill off. After 3 hours the crude product was allowed to cool and triturated with petroleum ether. The solid was filtered off and recrystallised from ethyl acetate/ petroleum ether to give 2-(2-ethoxyethyl)-N,N′-di(2-methoxyphenyl)malonodiamide (36.6 g, 47%), m.p. 132-133°. B. Preparation of 1-(2-methoxyphenyl)-4-oxo-6-methoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline 2-(2-Ethoxyethyl)-N,N′-di(2-methoxyphenyl)malonodiamide (31 g, 80 mmol) was stirred for 9 hours in diphenyl ether (120 ml) at reflux. The mixture was allowed to cool, diluted with petroleum ether, and the resulting solid filtered off. This was a mixture of the desired product plus 4-oxo-6-methoxy-2,3,4,5-tetrahydrofuro[3,2-c]quinoline. Repeated chromatography (silica gel, 1.5% methanolic ammonia in dichloromethane) followed by recrystallisation from ethyl acetate/petroleum ether gave a sample of 1-(2-methoxyphenyl)-4-oxo-6-methoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline (0.6 g), m.p. 204-205°. C₁₉H₁₈N₂O₃. 0.03EtOAc Found C 70.44, H 5.48, N 8.49 Requires C 70.66, H 5.66, N 8.62 The bulk of the material was recrystallised once from ethyl acetate/petroleum ether, then used in subsequent synthetic steps without further purification. Example 10 Preparation of 1-(2-methoxyphenyl)-4-chloro-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-Methoxyphenyl)-4-oxo-6-methoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline (9.55 g) was dissolved in phosphoryl chloride (100 ml) and heated at reflux for 2.5 hours. After cooling, the solution was poured onto ice, made alkaline with aqueous sodium hydroxide solution, and extracted with dichloromethane. The organic extract was dried and evaporated, and the crude product purified by chromatography (silica gel, 50-100% diethyl ether in petroleum ether). The first compound to elute was 4-chloro-6-methoxy-2,3-dihydrofuro[3,2-c]quinoline, m.p. 99-101°. Later fractions containing the desired product were recrystallised from ethyl acetate, then ethyl acetate/ethanol to give 1-(2-methoxyphenyl)-4-chloro-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline, m.p. 183-184°. C₁₉H₁₇ClN₂O₂ Found C 67.03, H 5.02, N 8.15, Cl 10.66 Requires C 66.96, H 5.03, N 8.22, Cl 10.40 Example 11 Preparation of 1-(2-methoxyphenyl)-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline hydrochloride A suspension of 1-(2-methoxyphenyl)-4-chloro-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline (2.5 g, 7.3 mmol) in ethanol (250 ml) was hydrogenated over 10% palladium on charcoal at an initial pressure of 4 bar. After 2.25 hours the solution was filtered through celite and evaporated. Crystallisation from ethanol/ethyl acetate gave 1-(2-methoxyphenyl)-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline hydrochloride as a hygroscopic solid (1.05 g, 42%), m.p. 213-214° (dec). C₁₉H₁₈N₂O₂. HCl. 0.3H₂O Found C 65.49, H 5.41, N 7.99 Requires C 65.53, H 5.67, N 8.04 The mother liquors from the crystallisation were converted to the free base to give an oil which slowly crystallised (1.15 g, 51%), m.p. 173-176°. Example 12 Preparation of 1-(2-methoxyphenyl)-4-amino-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-Methoxyphenyl)-4-oxo-6-methoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline (1.5 g) and phenyl phosphorodiamidate (2.5 g) were fused at 230°C. After 45 minutes the mixture was diluted with diphenyl ether (10 ml), further phenyl phosphorodiamidate (2 g) added, and heated for a further 15 minutes at 230°C. Aqueous sodium hydroxide was added and the product extracted into dichloromethane. Chromatography (silica gel, 2.5-4% methanolic ammonia in dichloromethane) to remove unchanged starting material was followed by recrystallisation from ethanol/ethyl acetate to yield 1-(2-methoxyphenyl) 4-amino-6-methoxy-2,3- dihydropyrrolo[3,2-c]quinoline (0.36 g), m.p. 244-247° (dec). C₁₉H₁₉N₃O₂. 0.3EtOH. 0.02EtOAc Found C 70.69, H 5.86, N 12.79 Requires C 70.85, H 6.00, N 12.95 Example 13 Preparation of 1-(2-methylphenyl)-4-dimethylamino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline A. Preparation of 2-(2-ethoxyethyl)-N,N′-di(2-methylphenyl)malonodiamide A mixture of o-methylaniline (74 ml, 0.68 mol) and diethyl 2-ethoxyethylmalonate (80 g, 0.31 mol) was heated to 220°C as nitrogen was bubbled slowly through the mixture, and ethanol allowed to distill off. After 2.5 hours the crude product was allowed to cool, and triturated with petroleum ether. The solid was filtered off and washed with petroleum ether to give 2-(2-ethoxyethyl)-N,N′-di(2-methylphenyl)malonodiamide (270 g), which was used without further purification. B. preparation of 1-(2-methylphenyl)-4-oxo-6-methyl-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline 2-(2-Ethoxyethyl)-N,N′-di(2-methylphenyl)malonodiamide (90 g) was stirred for 15 hours in diphenyl ether (250 ml) at reflux, then the diphenyl ether evaporated off in vacuo . Crystallisation of the residue from petroleum ether gave 1-(2-methylphenyl)-4-oxo-6-methyl-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline (21 g), which was used without further purification. C. Preparation of 1-(2-methylphenyl)-4-chloro-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-Methylphenyl)-4-oxo-6-methyl-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline (16 g) was dissolved in phosphoryl chloride (100 ml) and heated at reflux for 5 hours. After cooling, the solution was poured onto ice, made alkaline with aqueous sodium hydroxide solution, and extracted with dichloromethane, which was dried and evaporated. Crystallisation from ethyl acetate gave 1-(2-methylphenyl)-4-chloro-6-methyl-2,3-dihydropyrrolo- [3,2-c]quinoline, which was used without further purification. D. Preparation of 1-(2-methylphenyl)-4-dimethylamino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-Methylphenyl)-4-chloro-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline (1.5 g. 4.9 mmol) and dimethylamine (33% in ethanol, 150 ml) were heated to 180°C in a pressure vessel for 18 hours, then evaporated, taken up in dichloromethane, washed with sodium bicarbonate, dried and evaporated. Crystallisation from aqueous ethanol gave 1-(2-methylphenyl)-4-dimethylamino- 6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline (0.97 g,. 63%), m.p. 120-121°. C₂₁H₂₃N₃. 0.1H₂O Found C 79.06, H 7.31, N 13.20 Requires C 79.01, H 7.33, N 13.16 Example 14 Preparation of 1-(2-methylphenyl)-4-methylamino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-Methylphenyl)-4-chloro-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline (1.5 g, 4.9 mmol) and methylamine (33% in ethanol, 250 ml) were heated to 180°C in a pressure vessel for 24 hours, then evaporated. Crystallisation from aqueous ethanol gave 1-(2-methylphenyl)-4-methylamino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline (1.05 g, 71%), m.p. 165-167°. C₂₀H₂₁N₃. 0.1H₂O Found C 78.77, H 6.89, N 13.78 Requires C 78.71, H 7.00, N 13.77 Example 15 Preparation of 1-(2-methylphenyl)-4-amino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline Impure 1-(2-methylphenyl)-4-oxo-6-methyl-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline (10.0 g) and phenyl phosphorodiamidate (12 g) were fused at 230°C. After 30 minutes the mixture was diluted with diphenyl ether (50 ml), further phenyl phosphorodiamidate (4 g) added, and heated for a further 30 minutes at 230°C. Aqueous sodium hydroxide was added and the product extracted into dichloromethane. Chromatography (silica gel, 3% methanolic ammonia in dichloromethane) to remove unchanged starting material was followed by recrystallisation from ethanol to yield 1-(2-methylphenyl)-4-amino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline (1.51 g), m.p. 173-174°. C₁₉H₁₉N₃ Found C 78.80, H 6.70, N 14.55 Requires C 78.86, H 6.62, N 14.52 Example 16 Preparation of 1-(2-methylphenyl)-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-Methylphenyl)-4-chloro-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline (1.5 g) in ethanol (100 ml) was hydrogenated over 10% palladium on charcoal (0.25 g) at an initial pressure of 3 bar. After 7 hours the mixture was filtered through celite and evaporated. Conversion to free base and recrystallisation from ethyl acetate/petroleum ether yielded 1-(2-methylphenyl)-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline (0.41 g, 31 %), m.p. 109-110°. C₁₉H₁₈N₂ Found C 83.05, H 6.69, N 10.20 Requires C 83.18, H 6.61, N 10.21 Example 17 Preparation of 1-(2-methylphenyl)-4-methoxy-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-Methylphenyl)-4-chloro-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline (0.62 g, 2 mmol), sodium methoxide (1.0 g, 18.5 mmol) and methanol (30 ml) were heated to 170°C in a pressure vessel for 18 hours, then the solvent evaporated in vacuo . Conversion to free base, chromatography (silica gel, 40:60 dichloromethane/petroleum ether) and recrystallisation from methanol yielded 1-(2-methylphenyl)-4-methoxy-6-methyl-2,3-dihydropyrrolo- [3,2-c]quinoline (0.30 g), m.p. 107-108°. C₂₀H₂₀N₂O Found C 78.88, H 6.63, N 9.15 Requires C 78.92, H 6.62, N 9.20 Example 18 Preparation of 1-(2-methylphenyl)-4-(3-hydroxypropylamino)-6-methylpyrrolo[3,2-c]quinoline A. Preparation of 1-(2-methylphenyl)-4-oxo-6-methyl-4,5-dihydropyrrolo[3,2-c]quinoline 1-(2-Methylphenyl)-4-oxo-6-methyl-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline (9.25 g), diphenyl ether (75 ml) and 10% palladium on charcoal (1 g) were heated at reflux for 4 hours, cooled, diluted with ethyl acetate, and filtered through celite. Further dilution with ethyl acetate induced crystallisation of 1-(2-methylphenyl)-4-oxo-6-methyl-4,5-dihydropyrrolo[3,2-c]quinoline (6.68 g), m.p. 226-232°, which was used without further purification. B. Preparation of 1-(2-methylphenyl)-4-chloro-6-methylpyrrolo[3,2-c]quinoline 1-(2-Methylphenyl)-4-oxo-6-methyl-4-5-dihydropyrrolo[3,2-c]quinoline (4.75 g) and phosphoryl chloride (40 ml) were heated at reflux for 1.5 hours. The phosphoryl chloride was evaporated in vacuo, the residue poured onto ice and extracted with dichloromethane, which was dried and evaporated. Crystallisation from ethanol yielded 1-(2-methylphenyl)-4-chloro-6-methylpyrrolo[3,2-c]quinoline (4.76 g), m.p. 135-137°. C. Preparation of 1-(2-methylphenyl)-4-(3-hydroxypropylamino)-6-methylpyrrolo[3,2-c]quinoline 1-(2-Methylphenyl)-4-chloro-6-methylpyrrolo[3,2-c]quinoline (1.0 g) and 3-aminopropanol (3.0 g) were heated to 150°C for 3 hours. Chromatography (silica gel, 2% methanolic ammonia in dichloromethane) and recrystallisation from ethyl acetate/petroleum ether yielded 1-(2-methylphenyl)-4-(3-hydroxypropylamino)-6-methylpyrrolo[3,2-c]quinoline (0.57 g), m.p. 135-137°. C₂₂H₂₃N₃O. 0.02EtOAc Found C 76.16, H 6.75, N 12.15 Requires C 76.38, H 6.72, N 12.10 Example 19 Preparation of 1-(2-methylphenyl)-4-(2-hydroxyethylamino)-6-methylpyrrolo[3,2-c]quinoline 1-(2-Methylphenyl)-4-chloro-6-methylpyrrolo[3,2-c]quinoline (1.0 g) and ethanolamine (3.0 g) were heated to 150°C for 3 hours. Chromatography (silica gel, 2% methanolic ammonia in dichloromethane) and recrystallisation from ethyl acetate/petroleum ether yielded 1-(2-methylphenyl)-4-(2-hydroxyethylamino)-6-methylpyrrolo[3,2-c]quinoline (0.78 g), m.p. 187-188°. C₂₁H₂₁N₃O Found C 76.57, H 6.28, N 12.83 Requires C 76.11, H 6.39, N 12.68 Example 20 Preparation of 1-(2-methylphenyl)-4-methylamino-6-methylpyrrolo[3,2-c]quinoline 1-(2-Methylphenyl)-4-chloro-6-methylpyrrolo[3,2-c]quinoline (1.5 g, 4.9 mmol) and methylamine (33% in ethanol, 50 ml) were heated to 150°C in a pressure vessel for 16 hours, then the solvent evaporated. Chromatography (silica gel, 2% methanolic ammonia in dichloromethane) and recrystallisation from aqueous ethanol yielded 1-(2-methylphenyl)-4-methylamino-6-methylpyrrolo[3,2-c]quinoline (0.62 g), m.p. 129-130°. C₂₀H₁₉N₃ Found C 79.80, H 6.47, N 13.94 Requires C 79.70, H 6.35, N 13.94 Example 21 Preparation of 2-(methylphenyl)-4-methyl-6-fluoro-2,3-dihydropyrrolo[3,2-c]quinoline A. Preparation of 3-(2-chloroethyl)-4-chloro-8-fluoro-2-methylquinoline 2-Fluoroaniline (9.65 ml, 0.1 mol) and 2-acetyl-§-butyrolactone (10.76 ml, 0.1 mol) were heated to 120° for 1 hour, then 160° for 2 hours. The mixture was cooled, phosphoryl chloride (100 ml) added, and the resulting solution heated at reflux for 1.5 hours. After cooling, the mixture was poured onto ice and extracted with dichloromethane, which was washed with sodium bicarbonate solution, water and brine, dried and evaporated. Trituration with ether followed by recrystallisation from ethanol gave 3-(2-chloroethyl)-4-chloro-3-fluoro-2-methylquinoline (3.68 g), m.p. 101-103° B. Preparation of 2-(methylphenyl)-4-methyl-6-fluoro-2,3-dihydropyrrolo(3,2-c]quinoline 3-(2-Chloroethyl)-4-chloro-8-fluoro-2-methylquinoline (2.58 g, 10 mmol) and 2-methylaniline hydrochloride (2.87 g, 20 mmol) in 2-propanol (25 ml) were heated to 170° in a pressure vessel for 18 hours. The solvent was evaporated, the residue taken up in dichloromethane and washed with sodium bicarbonate solution. Evaporation of the dichloromethane, trituration with ether, and recrystallisation from methanol then ethyl acetate gave 2-(methylphenyl)-4-methyl-6-fluoro-2,3-dihydropyrrolo[3,2-c]quinoline (0.85 g), m.p. 209-211°. C₁₉H₁₇FN₂ Found C 78.24, H 5.87, N 9.59 Requires C 78.06, H 5.86, N 9.58 Example 22 Preparation of 1-(2-methylphenyl)-4-methylthio-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-Methylphenyl)-4-chloro-6-methyl-2,3-dihydro pyrrolo-[3,2-c]quinoline (1.54 g, 5 mmol) and sodium methanethiolate (1.40 g, 20 mmol) in 2-propanol (25 ml) were heated at 170° in a pressure vessel for 18 hours. The solvent was evaporated, the residue taken up in dichloromethane and washed with sodium bicarbonate solution. Chromatography (silica gel, dichloromethane) and crystallisation from methanol gave 1-(2-methylphenyl)-4-methylthio-6-methyl-2,3-dihydropyrrolo-[3,2-c]quinoline (0.8 g), m.p. 111-113°. C₂₀H₂₀N₂S. 0.2MeOH Found C 74.26, H 6.15, N 8.59, S 9.93 Require C 74.23, H 6.41, N 8.57, S 9.81 Example 23 Preparation of 1-(2-methylphenyl)-4-hydroxymethyl-2,3-dihydropyrrolo[3,2-c]quinoline A. Preparation of 1-(2-methylphenyl)-4-methyl-5-oxo-2,3-dihydropyrrolo[3,2-c]quinoline. 1-(2-Methylphenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinoline (15.0 g, 0.055 mol) was stirred at 0°C in chloroform (200 ml). A solution of m-chloroperoxybenzoic acid (9.5 g, 0.055 mol) in chloroform (100 ml) was added dropwise keeping the temperature below 5°C. The mixture was stirred for a further 30 minutes and the solvent then evaporated. The residue was chromatographed (silica gel, 2% methanolic ammonia in dichloromethane) to afford 1-(2-methylphenyl)-4-methyl-5-oxo-2,3-dihydropyrrolo[3,2-c]quinoline (1.8 g, 11.3%) m.p. 212-4°. B. Preparation of 1-(2-methylphenyl)-4-hydroxymethyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-Methylphenyl)-4-methyl-5-oxo-2,3-dihydropyrrolo[3,2-c]quinoline (3.5 g, 0.0155 mol) was heated in acetic anhydride (75 ml) over a steam bath for 30 minutes. The solvent was evaporated and the residue was again heated over a steam bath in 10% hydrochloric acid for 45 minutes. When cool the solution was neutralised with sodium bicarbonate and extracted into dichloromethane. The organic solution was dried and evaporated then chromatographed (silica gel, 2% methanolic ammonia in dichloromethane) to afford 1-(2-methylphenyl)-4-hydroxymethyl-2,3-dihydropyrrolo[3,2-c]quinoline as crystals from ethyl acetate (0.56 g, 16%) m.p. 164-6°. C₁₉H₁₈N₂O Requires: C 78.59, H 6.25, N 9.65 Found: C 78.32, H 6.25, N 9.58 Example 24 Preparation of 1-(2-methylphenyl)-5-oxo-7-methoxy-1,2,3,4,5,6- hexahydropyridino[3,2-c]quinoline A. Preparation of 1-(2-methylphenyl)-7-methoxy-6-oxo-1,2,3,4- tetrahydropyridino[3,2-c]quinoline 1-(2-methylphenyl)-7-methoxy-1,2,3,4-tetrahydropyridino-[3,2-c]quinoline (0.26 g, 0.85 mmol) was stirred at 0-5°C in chloroform (20 ml) and m-chloroperoxybenzoic acid (0.15 g) in chloroform (2 ml) was added. Stirring was continued at 0°C for 2 hours. The solvent was evaporated and the residue was chromatographed (silica gel, 2-3% methanolic ammonia in dichloromethane) to afford the required 1-(2-methylphenyl)-7-methoxy-6-oxo-1,2,3,4-tetrahydropyridino(3,2-c]quinoline (0.08 g, 29%). B. Preparation of 1-(2-methylphenyl)-5-oxo-7-methoxy-1,2,3,4,5,6-hexahydropyridino[3,2-c]quinoline 1-(2-methylphenyl)-7-methoxy-6-oxo-1,2,3,4-tetrahydropyridino-[3,2-c]quinoline (0.08 g, 0.25 mmol) was heated over a steam bath in acetic anhydride (10 ml) for 40 minutes. The solvent was evaporated and the residue was reheated over a steam bath in 10% hydrochloric acid (10 ml) for 30 minutes. The product was extracted into chloroform and chromatographed (silica gel, 1% methanol in chloroform) to give 1-(2-methylphenyl)-5-oxo-7-methoxy-1,2,3,4,5,6-hexahydropyridino[3,2-c]- quinoline (5 ml) m.p. 203-5°. Example 25 Preparation of 1-(2-methylphenyl)-4-(4-hydroxybutylamino)-6-methylpyrrolo[3,2-c]quinoline hydrochloride 1-(2-methylphenyl)4-chloro-6-methylpyrrolo[3,2-c]quinoline (1.0 g, 3.26 mmol) was dissolved in 4-aminobutanol (3.0 g) and stirred for 6 hours at 170°. Chromatography (silica gel, 2% methanolic ammonia in dichloromethane), conversion to the hydrochloride and recrystallisation from ethanol/ether gave 1-(2-methylphenyl)-4-(4-hydroxybutylamino)-6-methylpyrrolo[3,2-c]quinoline hydrochloride (0.8 g), m.p. 176-178°. C₂₃H₂₅N₃O.HCl.0.2H₂O Found C 69.31, H 6.67, N 10.53, Cl 8.59 Requires C 69.30, H 6.65, N 10.54, Cl 8.89 Example 26 Preparation of 1-(4-hydroxy-2-methylphenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinoline A solution of 4-chloro-3-chloroethyl-2-methylquinoline hydrochloride (1.28 g, 4.6 mmol) and 4-hydroxy-2-methylaniline (1.13 g, 9.2 mmol) in n-butanol (20 ml) was heated at reflux under a nitrogen atmosphere for 20 hours, then evaporated. Chromatography (silica gel, 5-7% methanolic ammonia in dichloromethane) and recrystallisation from aqueous methanol gave 1-(4-hydroxy2-methylphenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinoline (0.16 g), m.p. 315-318°. C₁₉H₁₈N₂O Found C 78.55, H 6.27, N 9.56 Requires C 78.59, H 6.25, N 9.65 Example 27 Preparation of 1-(4-methoxy-2-methylphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline A mixture of 2-methyl-3-(2-chloroethyl)-4-chloro-8-methoxyquinoline hydrochloride (15.33 g, 50 mmol), 4-methoxy-2-methylaniline (9.0 ml, 70 mmol) and 2-propanol (200 ml) was heated at reflux for 2 days, then evaporated. The crude product was triturated with ether then recrystallised twice from aqueous ethanol to give the title compound (3.16 g), m.p. 163-167°. C₂₁C₂₂N₂O₂. 0.9H₂O Found C 72.02, H 6.84, N 7.98 Requires C 71.93, H 6.84, N 7.99 Example 28 Preparation of 1-(2,6-dimethylphenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinoline A mixture of 2-methyl-3-(2-chloroethyl)-4-chloroquinoline hydrochloride (13.8 g, 50 mmol), 2,6-dimethylaniline (12.5 ml, 100 mmol) and 2-propanol (400 ml) was heated to 140° for 5 days in a pressure vessel, then cooled and evaporated. The crude product was converted to free base and chromatographed (silica gel, methanolic ammonia in dichloromethane). Recrystallisation from aqueous methanol followed by aqueous ethanol gave 1-(2,6-dimethylphenyl)-4-methyl- 2,3-dihydropyrrolo[3,2-c]quinoline (1.52 g), m.p. 149-152°. C₂₀H₂₀N₂ Found C 83.02, H 6.99, N 9.65 Requires C 83.30, H 6.99, N 9.71 Example A A tablet for oral administration is prepared by combining into a 9 mm tablet. Example B An injection for parenteral administration was prepared from the following Compound of Structure 1 6.68%(w:v) 1M citric acid 30%(v:v) sodium hydroxide (qs) to pH 3.2 water for injection EP to 100 ml The compound of Structure 1 was dissolved in the citric acid and the pH slowly adjusted to pH 3.2 with the sodium hydroxide solution. The solution was then made up to 100 ml with water, sterilised by filtration and sealed into appropriately sized ampoules and vials. Biological Data. (A) H ⁺K⁺ ATPase Activity . The effects of a single high concentration (100 µM) of a compound of structure (I) on K-stimulated ATPase activity in lyophilised gastric vesicles was determined. Preferred compounds of structure (I) were also tested over a range of concentrations to determine IC₅₀ values. (i) Preparation of lyophilised gastric vesicles (H/K-ATPase) . Lyophilised gastric vesicles were prepared from pig fundic mucosa after the method of Keeling et. al. (Biochem. Pharmacol., 34, 2967, 1985). (ii) K⁺-stimulated ATPase activity . K⁺-stimulated ATPase activity was determined at 37°C in the presence of the following : 10 mM Pipes/Tris buffer pH 7.0, 2 mM MgSO₄, 1 mM KCl, 2 mM Na₂ATP and 3 µg protein/ml lyophilised gastric vesicles. After incubation for 30 minutes, the inorganic phosphate hydrolysed from ATP was determined by the method of Yoda and Hokin (Biochem. Biophys. Res. Commun. 40, 880, 1970). Compounds of structure (I) were dissolved in dimethylsulphoxide which up to the highest concentration used had no effect on K⁺-stimulated ATPase activity. The effect of the highest concentration of each compound of structure (I) on the recovery of a standard amount of inorganic phosphate was also determined. (iii) Results . The compounds of each of examples 1 to 16 and 18 to 21, 23 and 25 to 28 were assayed in the above-noted screen and found to have IC₅₀ values in the range of from 0.17 to 33 µM.

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE A compound of structure (I) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₄alkanoyl, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹ are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; provided that (i) when R¹ to R⁷ are each hydrogen, one of R⁸ and R⁹ is hydrogen and the other is hydrogen or methoxy and R¹⁰ is methyl, A is -(CH₂)₃- or -CH=CH-; (ii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R⁷ is hydroxy and R¹⁰ is methyl, A is -(CH₂)₃-or -CH=CH-; (iii) when R¹ to R⁹ are each hydrogen and R¹⁰ is chlorine, A is -(CH₂)₃-; (iv) when R¹ to R¹⁰ are each hydrogen, A is -(CH₂)₃-; (v) when R¹ and R² and R⁴ to R¹⁰ are each hydrogen and R³ is methoxy, A is -(CH₂)₂- or -(CH₂)₃-; (vi) when R² to R⁹ are each hydrogen, R¹⁰ is methyl and R¹ is hydrogen, hydroxy or methoxy, A is -(CH₂)₃- or -CH=CH-; (vii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R¹⁰ is methyl and R⁷ is methyl or methoxy, A is -(CH₂)₃- or -CH=CH-; (viii) when R¹ to R⁸ are each hydrogen, R⁹ is chlorine and R¹⁰ is methyl, A is -(CH₂)₃ or -CH=CH-, (ix) when R¹ and R² and R⁴ to R⁹ are each hydrogen, R¹⁰ is methyl and R³ is hydrogen or methoxy A is -(CH₂)₂- or -(CH₂)₃-, or a pharmaceutically acceptable salt thereof. A compound according to Claim 1 in which A is -(CH₂)₂-. A compound according to Claim 1 in which A is -CH=CH-. A compound according to any one of claims 1 to 3 in which R¹⁰ is a group -NR¹¹R¹² in which R¹¹ and R¹² are as described for structure (I). A compound according to any one of claims 1 to 3 in which R¹⁰ is C₁₋₆alkyl. A compound according to any one of Claims 1 to 5 in which R¹ is C₁₋₆alkyl or C₁₋₆alkoxy. A compound according to Claim 6 in which R⁹ is C₁₋₆alkyl. A compound according to Claim 1 which is 1-(2-methoxyphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methyl-6-hydroxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methyl-6-methoxypyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4,6-dimethyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(4-methoxy-2-methylphenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-7-methoxy-1,2,3,4-tetrahydropyridino[3,2-c]quinoline 1-(2-methoxyphenyl)-4-oxo-6-methoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline 1-(2-methoxyphenyl)-4-chloro-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methoxyphenyl)-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline hydrochloride 1-(2-methoxyphenyl)-4-amino-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-dimethylamino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methylamino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-amino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methoxy-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-(3-hydroxypropylamino)-6-methylpyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-(2-hydroxyethylamino)-6-methylpyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methylamino-6-methylpyrrolo[3,2-c]quinoline A pharmaceutical composition comprising a compound of structure (IB) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆ alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹ are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; provided that ( i) when R² to R⁹ are each hydrogen, R¹⁰ is methyl and R¹ is hydrogen, hydroxy or methoxy, A is -(CH₂)₃-or -CH=CH-; ( ii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R¹⁰ is methyl and R⁷ is methyl or methoxy, A is -(CH₂)₃- or -CH=CH-; (iii) when R¹ to R⁸ are each hydrogen, R⁹ is chlorine and R¹⁰ is methyl, A is -(CH₂)₃- or -CH=CH-, or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier. A compound of structure (IA) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹ are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; provided that ( i) when R² to R⁹ are each hydrogen, R¹⁰ is methyl and R¹ is hydrogen, hydroxy or methoxy, A is -(CH₂)₃-or -CH=CH-; ( ii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R¹⁰ is methyl and R⁷ is methyl or methoxy, A is -(CH₂)₃- or -CH=CH-; (iii) when R¹ to R⁸ are each hydrogen, R⁹ is chlorine and R¹⁰ is methyl, A is -(CH₂)₃ or -CH=CH-, or a pharmaceutically acceptable salt thereof for use as a therapeutic agent. Use of a compound of structure (IB) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹ are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; or a pharmaceutically acceptable salt thereof for the preparation of a medicament for use in the treatment of ulcer disease. A process for the preparation of a compound according to Claim 1 which comprises (a) for compounds in which R¹⁰ is hydrogen or C₁₋₆alkyl, cyclisation of a compound of structure (II) in which R¹ to R⁴ and R¹⁰ are as described for structure (I), n is 2 or 3 and X¹ and X² are leaving groups, in the presence of a compound of structure (III) in which R⁵ to R⁹ are as described for structure (I); or (b) for compounds in which R¹⁰ is other than C₁₋₆alkyl reaction of a compound of structure (IV) in which R¹ to R⁹ and A are as described for structure (I) which a nucleophilic reagent providing the group R¹⁰, and optionally thereafter converting one group R¹⁰ into another group R¹⁰; oxidising a compound in which A is (CH₂)₂ to a compound in which A is -CH=CH-; removing any protecting groups; forming a pharmaceutically acceptable salt. Claims for the following Contracting State: ES A process for the preparation of a compound of structure (I) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₄alkanoyl, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹ are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; provided that (i) when R¹ to R⁷ are each hydrogen, one of R⁸ and R⁹ is hydrogen and the other is hydrogen or methoxy and R¹⁰ is methyl, A is -(CH₂)₃- or -CH=CH-; (ii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R⁷ is hydroxy and R¹⁰ is methyl, A is -(CH₂)₃-or -CH=CH-; (iii) when R¹ to R⁹ are each hydrogen and R¹⁰ is chlorine, A is -(CH₂)₃-; (iv) when R¹ to R¹⁰ are each hydrogen, A is -(CH₂)₃-; (v) when R¹ and R² and R⁴ to R¹⁰ are each hydrogen and R³ is methoxy, A is -(CH₂)₂- or -(CH₂)₃-; (vi) when R² to R⁹ are each hydrogen, R¹⁰ is methyl and R¹ is hydrogen, hydroxy or methoxy, A is -(CH₂)₃-or -CH=CH-; (vii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R¹⁰ is methyl and R⁷ is methyl or methoxy, A is -(CH₂)₃- or -CH=CH-; (viii) when R¹ to R⁸ are each hydrogen, R⁹ is chlorine and R¹⁰ is methyl, A is -(CH₂)₃ or -CH=CH-, (ix) when R¹ and R² and R⁴ to R⁹ are each hydrogen, R¹⁰ is methyl and R³ is hydrogen or methoxy A is -(CH₂)₂- or -(CH₂)₃-, or a pharmaceutically acceptable salt thereof, which comprises (a) for compounds in which R¹⁰ is hydrogen or C₁₋₆alkyl, cyclisation of a compound of structure (II) in which R¹ to R⁴ and R¹⁰ are as described for structure (I), n is 2 or 3 and X¹ and X² are leaving groups, in the presence of a compound of structure (III) in which R⁵ to R⁹ are as described for structure (I); or (b) for compounds in which R¹⁰ is other than C₁₋₆alkyl reaction of a compound of structure (IV) in which R¹ to R⁹ and A are as described for structure (I) which a nucleophilic reagent providing the group R¹⁰, and optionally thereafter converting one group R¹⁰ into another group R¹⁰; oxidising a compound in which A is (CH₂)₂ to a compound in which A is -CH=CH-; removing any protecting groups; forming a pharmaceutically acceptable salt. A process according to claim 1 in which in the compound of structure (I) A is -(CH₂)₂-. A process according to claim 1 in which in the compound of structure (I) A is CH=CH. A process according to any one of claims 1 to 3 in which in the compound of structure (I) R¹⁰ is a group -NR¹¹R¹² in which R¹¹ and R¹² are as described for structure (I). A process according to any one of claims 1 to 3 in which in the compound of structure (I) R¹⁰ is C₁₋₆alkyl. A process according to any one of Claims 1 to 5 in which in the compound of structure (I) R¹ is C₁₋₆alkyl or C₁₋₆alkoxy. A process according to Claim 6 in which in the compound of structure (I) R⁹ is C₁₋₆alkyl. A process according to Claim 1 in which the compound of structure (I) is 1-(2-methoxyphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methyl-6-hydroxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methyl-6-methoxypyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4,6-dimethyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(4-methoxy-2-methylphenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-7-methoxy-1,2,3,4-tetrahydropyridino[3,2-c]quinoline 1-(2-methoxyphenyl)-4-oxo-6-methoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline 1-(2-methoxyphenyl)-4-chloro-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methoxyphenyl)-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline hydrochloride 1-(2-methoxyphenyl)-4-amino-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-dimethylamino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methylamino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-amino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methoxy-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-(3-hydroxypropylamino)-6-methylpyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-(2-hydroxyethylamino)-6-methylpyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methylamino-6-methylpyrrolo[3,2-c]quinoline A process for preparing a pharmaceutical composition which comprises bringing into association a compound of structure (IB) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹ are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; provided that ( i) when R² to R⁹ are each hydrogen, R¹⁰ is methyl and R¹ is hydrogen, hydroxy or methoxy, A is -(CH₂)₃-or -CH=CH-; ( ii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R¹⁰ is methyl and R⁷ is methyl or methoxy, A is -(CH₂)₃- or -CH=CH-; (iii) when R¹ to R⁸ are each hydrogen, R⁹ is chlorine and R¹⁰ is methyl, A is -(CH₂)₃- or -CH=CH-, or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier. A process according to claim 9 in which the compound of structure (IB) us a compound as described in claim 8. A compound of structure (IA) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹ are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; provided that ( i) when R² to R⁹ are each hydrogen, R¹⁰ is methyl and R¹ is hydrogen, hydroxy or methoxy, A is -(CH₂)₃- or -CH=CH-; ( ii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R¹⁰ is methyl and R⁷ is methyl or methoxy, A is -(CH₂)₃- or -CH=CH-; (iii) when R¹ to R⁸ are each hydrogen, R⁹ is chlorine and R¹⁰ is methyl, A is -(CH₂)₃ or -CH=CH-, or a pharmaceutically acceptable salt thereof for use as a therapeutic agent. Use of a compound of structure (IB) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹ are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; or a pharmaceutically acceptable salt thereof for the preparation of a medicament for use in the treatment of ulcer disease. Claims for the following Contracting State: GR A process for the preparation of a compound of structure (I) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₄alkanoyl, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹ are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; provided that (i) when R¹ to R⁷ are each hydrogen, one of R⁸ and R⁹ is hydrogen and the other is hydrogen or methoxy and R¹⁰ is methyl, A is -(CH₂)₃- or -CH=CH-; (ii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R⁷ is hydroxy and R¹⁰ is methyl, A is -(CH₂)₃-or -CH=CH-; (iii) when R¹ to R⁹ are each hydrogen and R¹⁰ is chlorine, A is -(CH₂)₃-; (iv) when R¹ to R¹⁰ are each hydrogen, A is -(CH₂)₃-; (v) when R¹ and R² and R⁴ to R¹⁰ are each hydrogen and R³ is methoxy, A is -(CH₂)₂- or -(CH₂)₃-; (vi) when R² to R⁹ are each hydrogen, R¹⁰ is methyl and R¹ is hydrogen, hydroxy or methoxy, A is -(CH₂)₃- or -CH=CH-; (vii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R¹⁰ is methyl and R⁷ is methyl or methoxy, A is -(CH₂)₃- or -CH=CH-; (viii) when R¹ to R⁸ are each hydrogen, R⁹ is chlorine and R¹⁰ is methyl, A is -(CH₂)₃ or -CH=CH-, (ix) when R¹ and R² and R⁴ to R⁹ are each hydrogen, R¹⁰ is methyl and R³ is hydrogen or methoxy, A is -(CH₂)₂- or -(CH₂)₃-, or a pharmaceutically acceptable salt thereof, which comprises (a) for compounds in which R¹⁰ is hydrogen or C₁₋₆alkyl, cyclisation of a compound of structure (II) in which R¹ to R⁴ and R¹⁰ are as described for structure (I), n is 2 or 3 and X¹ and X² are leaving groups, in the presence of a compound of structure (III) in which R⁵ to R⁹ are as described for structure (I); or (b) for compounds in which R¹⁰ is other than C₁₋₆alkyl reaction of a compound of structure (IV) in which R¹ to R⁹ and A are as described for structure (I) which a nucleophilic reagent providing the group R¹⁰, and optionally thereafter converting one group R¹⁰ into another group R¹⁰; oxidising a compound in which A is (CH₂)₂ to a compound in which A is -CH=CH-; removing any protecting groups; forming a pharmaceutically acceptable salt. A process according to claim 1 in which in the compound of structure (I) A is -(CH₂)₂-. A process according to claim 1 in which in the compound of structure (I) A is CH=CH. A process according to any one of claims 1 to 3 in which in the compound of structure (I) R¹⁰ is a group -NR¹¹R¹² in which R¹¹ and R¹² are as described for structure (I). A process according to any one of claims 1 to 3 in which in the compound of structure (I) R¹⁰ is C₁₋₆alkyl. A process according to any one of Claims 1 to 5 in which in the compound of structure (I) R¹ is C₁₋₆alkyl or C₁₋₆alkoxy. A process according to Claim 6 in which in the compound of structure (I) R⁹ is C₁₋₆alkyl. A process according to Claim 1 in which the compound of structure (I) is 1-(2-methoxyphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methyl-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methyl-6-hydroxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methyl-6-methoxypyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4,6-dimethyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(4-methoxy-2-methylphenyl)-4-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-7-methoxy-1,2,3,4-tetrahydropyridino[3,2-c]quinoline 1-(2-methoxyphenyl)-4-oxo-6-methoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline 1-(2-methoxyphenyl)-4-chloro-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methoxyphenyl)-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline hydrochloride 1-(2-methoxyphenyl)-4-amino-6-methoxy-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-dimethylamino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methylamino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-amino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methoxy-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-(3-hydroxypropylamino)-6-methylpyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-(2-hydroxyethylamino)-6-methylpyrrolo[3,2-c]quinoline 1-(2-methylphenyl)-4-methylamino-6-methylpyrrolo[3,2-c]quinoline A process for preparing a pharmaceutical composition which comprises bringing into association a compound of structure (IB) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹ are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; provided that ( i) when R² to R⁹ are each hydrogen, R¹⁰ is methyl and R¹ is hydrogen, hydroxy or methoxy, A is -(CH₂)₃- or -CH=CH-; ( ii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R¹⁰ is methyl and R⁷ is methyl or methoxy, A is -(CH₂)₃- or -CH=CH-; (iii) when R¹ to R⁸ are each hydrogen, R⁹ is chlorine and R¹⁰ is methyl, A is -(CH₂)₃- or -CH=CH-, or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier. A process according to claim 9 in which the compound of structure (IB) us a compound as described in claim 8. A compound of structure (IA) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; provided that ( i) when R² to R⁹ are each hydrogen, R¹⁰ is methyl and R¹ is hydrogen, hydroxy or methoxy, A is -(CH₂)₃- or -CH=CH-; ( ii) when R¹ to R⁶ and R⁸ and R⁹ are each hydrogen, R¹⁰ is methyl and R⁷ is methyl or methoxy, A is -(CH₂)₃- or -CH=CH-; (iii) when R¹ to R⁸ are each hydrogen, R⁹ is chlorine and R¹⁰ is methyl, A is -(CH₂)₃ or -CH=CH-, or a pharmaceutically acceptable salt thereof for use as a therapeutic agent. Use of a compound of structure (IB) in which R¹ to R⁴ are the same or different and are each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R¹ to R⁴ are hydrogen. R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, provided that at least two of R⁵ to R⁹ are hydrogen; R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂) n OH in which n is 0 to 4 or a group -NR¹¹R¹² in which R¹¹ and R¹² are the same or different and are each hydrogen or C₁₋₆alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring; and A is -(CH₂)₂-, -(CH₂)₃- or -CH=CH-; or a pharmaceutically acceptable salt thereof for the preparation of a medicament for use in the treatment of ulcer disease.

Inventors: BROWN, THOMAS HENRY, IFE, ROBERT JOHN, LEACH, COLIN ANDREW
Applicants: SMITHKLINE BEECHAM INTERCREDIT B.V.
Application year: 1988
Main classification: C07D471
IPC codes: C07D471, A61P1, A61K31, C07D215, A61P35